Hypertension is a common disease encountered in dental setting. Its wide spreading, terrible consequences, and life-long treatment require an attentive approach by dentists. Hypertension management in dental office includes disease recognition and correct measurement, knowledge of its treatment and oral adverse effects, and risk assessment for dental treatment. Dentist role in screening undiagnosed and undertreated hypertension is very important since this may lead to improved monitoring and treatment. 1. Introduction Hypertension is defined as values >140？mmHg SBP and/or >90？mmHg DBP, based on the evidence from RCTs that in patients with these BP values treatment-induced BP reductions are beneficial (Table 1) [1]. The same classification is used in young, middle-aged, and elderly subjects, whereas different criteria, based on percentiles, are adopted in children and teenagers for whom data from interventional trials are not available [1]. Table 1: Definitions and classification of office blood pressure levels (mmHg) a [ 1]. JNC 7 introduced in 2003 the category of prehypertension, which is defined as SBP of 120 to 139？mmHg and DBP of 80 to 89？mmHg (Table 2) [2]. Patients with prehypertension are at increased risk of developing hypertension, those with blood pressure values 130–139/80–89？mmHg have a two times greater risk of developing hypertension than those with lower values [3]. Table 2: JNC 7 classification of hypertension [ 2]. Hypertension is a highly prevalent cardiovascular disease, which affects over 1 billion people worldwide [2]. Although more than 70% of hypertensive patients are aware of the disease, only 23–49% are treated, and fewer (20%) achieving control [2, 4, 5]. Hypertension prevalence varies by age, race, education, and so forth. According to ESC-ESH guidelines in 2013, there are limited comparable data available on the prevalence of hypertension and the temporal trends of BP values in different European countries [6]. Overall the prevalence of hypertension appears to be around 30–45% of the general population, with a steep increase with ageing. There also appear to be noticeable differences in the average BP levels across countries, with no systematic trends towards BP changes in the past decade [7–29]. A permanent high blood pressure (BP) affects blood vessels in the kidneys, heart, and brain, increasing the incidence of renal and cardiac coronary heart disease and stroke. Hypertension was called the “silent killer” because it often affects target organs (kidney, heart, brain, eyes) before the appearance of clinical symptoms. 2.
References
[1]
G. Mancia, R. Fagard, K. Narkiewicz et al., “ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC),” Journal of Hypertension, vol. 25, no. 9, pp. 1751–1762, 2007.
[2]
A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report,” Journal of the American Medical Association, vol. 289, no. 19, pp. 2560–2572, 2003.
[3]
R. S. Vasan, M. G. Larson, E. P. Leip et al., “Impact of high-normal blood pressure on the risk of cardiovascular disease,” The New England Journal of Medicine, vol. 345, no. 18, pp. 1291–1297, 2001.
[4]
J. Hogan and J. Radhakrishnan, “The assessment and importance of hypertension in the dental setting,” Dental Clinics of North America, vol. 56, pp. 731–745, 2012.
[5]
M. Dorobantu, R. O. Darabont, E. Badila, and S. Ghiorghe, “Prevalence, awareness, treatment, and control of hypertension in Romania: results of the SEPHAR study,” International Journal of Hypertension, vol. 2010, Article ID 970694, 6 pages, 2010.
[6]
M. Pereira, N. Lunet, A. Azevedo, and H. Barros, “Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries,” Journal of Hypertension, vol. 27, no. 5, pp. 963–975, 2009.
[7]
N. Danon-Hersch, P. Marques-Vidal, P. Bovet et al., “Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general population: the co laus study,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 16, no. 1, pp. 66–72, 2009.
[8]
B. Altun, M. Arici, G. Nergizoglu et al., “Prevalence, awareness, treatment and control of hypertension in Turkey (the Patent study) in 2003,” Journal of Hypertension, vol. 23, no. 10, pp. 1817–1823, 2005.
[9]
N. T. Aytekin, K. Pala, E. Irgil, N. Akis, and H. Aytekin, “Distribution of blood pressures in Gemlik district, north-west Turkey,” Health and Social Care in the Community, vol. 10, no. 5, pp. 394–401, 2002.
[10]
A. D. Efstratopoulos, S. M. Voyaki, A. A. Baltas et al., “Prevalence, awareness, treatment and control of hypertension in Hellas, Greece: the hypertension study in general practice in Hellas (HYPERTENSHELL) national study,” American Journal of Hypertension, vol. 19, no. 1, pp. 53–60, 2006.
[11]
M. E. Macedo, M. J. Lima, A. O. Silva, P. Alcantara, V. Ramalhinho, and J. Carmona, “Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study,” Journal of Hypertension, vol. 23, no. 9, pp. 1661–1666, 2005.
[12]
T. Psaltopoulou, P. Orfanos, A. Naska, D. Lenas, D. Trichopoulos, and A. Trichopoulou, “Prevalence, awareness, treatment and control of hypertension in a general population sample of adults in the Greek EPIC study,” International Journal of Epidemiology, vol. 33, no. 6, pp. 1345–1352, 2004.
[13]
P. A. Sarafidis, A. Lasaridis, S. Gousopoulos et al., “Prevalence, awareness, treatment and control of hypertension in employees of factories of northern Greece: the Naoussa study,” Journal of Human Hypertension, vol. 18, no. 9, pp. 623–629, 2004.
[14]
D. B. Panagiotakos, C. H. Pitsavos, C. Chrysohoou et al., “Status and management of hypertension in Greece: role of the adoption of a mediterranean diet: the Attica study,” Journal of Hypertension, vol. 21, no. 8, pp. 1483–1489, 2003.
[15]
J. R. Banegas, A. Graciani, J. J. de la Cruz-Troca, L. M. Leon-Munoz, P. Guallar-Castillon, and A. Coca, “Achievement of cardiometabolic targets in aware hypertensive patients in Spain: a nationwide population-based study,” Hypertension, vol. 60, pp. 898–905, 2012.
[16]
P. Primatesta and N. R. Poulter, “Improvement in hypertension management in England: results from the health survey for England 2003,” Journal of Hypertension, vol. 24, no. 6, pp. 1187–1192, 2006.
[17]
C. Meisinger, M. Heier, H. Volzke et al., “Regional disparities of hypertension prevalence and management within Germany,” Journal of Hypertension, vol. 24, no. 2, pp. 293–299, 2006.
[18]
C. Agyemang, J. Ujcic-Voortman, D. Uitenbroek, M. Foets, and M. Droomers, “Prevalence and management of hypertension among Turkish, Moroccan and native Dutch ethnic groups in Amsterdam, the Netherlands: the Amsterdam health monitor survey,” Journal of Hypertension, vol. 24, no. 11, pp. 2169–2176, 2006.
[19]
C. Agyemang, N. Bindraban, G. Mairuhu, G. Montfrans, R. Koopmans, and K. Stronks, “Prevalence, awareness, treatment, and control of hypertension among black surinamese, south Asian surinamese and white Dutch in Amsterdam, the Netherlands: the SUNSET study,” Journal of Hypertension, vol. 23, no. 11, pp. 1971–1977, 2005.
[20]
T. Scheltens, M. L. Bots, M. E. Numans, D. E. Grobbee, and A. W. Hoes, “Awareness, treatment and control of hypertension: the “rule of halves” in an era of risk-based treatment of hypertension,” Journal of Human Hypertension, vol. 21, no. 2, pp. 99–106, 2007.
[21]
T. Zdrojewski, P. Szpakowski, P. Bandosz et al., “Arterial hypertension in Poland in 2002,” Journal of Human Hypertension, vol. 18, no. 8, pp. 557–562, 2004.
[22]
R. Cifkova, Z. Skodova, V. Lanska et al., “Prevalence, awareness, treatment, and control of hypertension in the Czech Republic. results of two nationwide cross-sectional surveys in 1997/1998 and 2000/2001, Czech post-MONICA study,” Journal of Human Hypertension, vol. 18, no. 8, pp. 571–579, 2004.
[23]
A. Scuteri, S. S. Najjar, M. Orru et al., “Age and gender-specific awareness, treatment, and control of cardiovascular risk factors and subclinical vascular lesions in a founder population: the Sardi NIA Study,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 19, no. 8, pp. 532–541, 2009.
[24]
M. Kastarinen, R. Antikainen, M. Peltonen et al., “Prevalence, awareness and treatment of hypertension in Finland during 1982–2007,” Journal of Hypertension, vol. 27, no. 8, pp. 1552–1559, 2009.
[25]
E. Falaschetti, M. Chaudhury, J. Mindell, and N. Poulter, “Continued improvement in hypertension management in England: results from the health survey for England 2006,” Hypertension, vol. 53, no. 3, pp. 480–486, 2009.
[26]
C. Erem, A. Hacihasanoglu, M. Kocak, O. Deger, and M. Topbas, “Prevalence of prehypertension and hypertension and associated risk factors among Turkish adults: Trabzon hypertension study,” Journal of Public Health, vol. 31, no. 1, pp. 47–58, 2009.
[27]
S. Costanzo, A. Di Castelnuovo, F. Zito et al., “Prevalence, awareness, treatment and control of hypertension in healthy unrelated male-female pairs of European regions: the dietary habit profile in European communities with different risk of myocardial infarction: the impact of migration as a model of gene-environment interaction project,” Journal of Hypertension, vol. 26, no. 12, pp. 2303–2311, 2008.
[28]
E. Cinteza and M. Balgradean, “Hypertension in Romanian children and adolescents: a cross-sectional survey,” Maedica, vol. 8, no. 1, pp. 5–10, 2013.
[29]
M. Doroban？u, R. Darabont, S. Ghiorghe et al., “Profile of the Romanian hypertensive patient data from SEPHAR II study,” Romanian Journal of Internal Medicine, vol. 50, no. 4, pp. 285–296, 2012.
[30]
N. M. Kaplan, “Primary hypertension. from pathophysiology to prevention,” Archives of Internal Medicine, vol. 156, no. 17, pp. 1919–1920, 1996.
[31]
H. Snieder, G. A. Harshfield, and F. A. Treiber, “Heritability of blood pressure and hemodynamics in African- and European-American youth,” Hypertension, vol. 41, no. 6, pp. 1196–1201, 2003.
[32]
M. S. Kaplan and A. Nunes, “The psychosocial determinants of hypertension,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 13, no. 1, pp. 52–59, 2003.
[33]
N. M. Kaplan, “Management of hypertensive patients with multiple cardiovascular risk factors,” American Journal of Hypertension, vol. 14, no. 6, part 2, pp. 221S–224S, 2001.
[34]
J. He, P. K. Whelton, L. J. Appel, J. Charleston, and M. J. Klag, “Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension,” Hypertension, vol. 35, no. 2, pp. 544–549, 2000.
[35]
W. M. Vollmer, F. M. Sacks, J. Ard et al., “Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial,” Annals of Internal Medicine, vol. 135, no. 12, pp. 1019–1028, 2001.
[36]
F. M. Sacks, L. P. Svetkey, W. M. Vollmer et al., “Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet,” The New England Journal of Medicine, vol. 344, no. 1, pp. 3–10, 2001.
[37]
S. P. Whelton, A. Chin, X. Xin, and J. He, “Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials,” Annals of Internal Medicine, vol. 136, no. 7, pp. 493–503, 2002.
[38]
X. Xin, J. He, M. G. Frontini, L. G. Ogden, O. I. Motsamai, and P. K. Whelton, “Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials,” Hypertension, vol. 38, no. 5, pp. 1112–1117, 2001.
[39]
J. A. Staessen, J. G. Wang, and L. Thijs, “Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003,” Journal of Hypertension, vol. 21, no. 6, pp. 1055–1076, 2003.
[40]
A. V. Chobanian and M. Hill, “National heart, lung, and blood institute workshop on sodium and blood pressure: a critical review of current scientific evidence,” Hypertension, vol. 35, no. 4, pp. 858–863, 2000.
[41]
J. P. Kooman, F. M. Van der Sande, and K. M. Leunissen, “Sodium, blood pressure and cardiovascular pathology: is it all volaemia?” Nephrology Dialysis Transplantation, vol. 19, no. 5, pp. 1046–1049, 2004.
[42]
S. J. Mann, “Drug therapy for resistant hypertension: simplifying the approach,” Journal of Clinical Hypertension, vol. 13, no. 2, pp. 120–130, 2011.
[43]
K. M. Habbab, D. R. Moles, and S. R. Porter, “Potential oral manifestations of cardiovascular drugs,” Oral Diseases, vol. 16, no. 8, pp. 769–773, 2010.
[44]
J. Guggenheimer and P. A. Moore, “Xerostomia: etiology, recognition and treatment,” Journal of the American Dental Association, vol. 134, no. 1, pp. 61–69, 2003.
[45]
L. M. Wing, J. L. Reid, and D. S. Davies, “Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension,” European Journal of Clinical Pharmacology, vol. 12, no. 6, pp. 463–469, 1977.
[46]
J. Breidthardt, H. Schumacher, and L. Mehlburger, “Long-term (5？year) experience with transdermal clonidine in the treatment of mild to moderate hypertension,” Clinical Autonomic Research, vol. 3, no. 6, pp. 385–390, 1993.
[47]
W. W. Herman, J. L. Konzelman Jr., and L. M. Prisant, “New national guidelines on hypertension: a summary for dentistry,” Journal of the American Dental Association, vol. 135, no. 5, pp. 576–584, 2004.
[48]
J. S. Ellis, R. A. Seymour, J. G. Steele, P. Robertson, T. J. Butler, and J. M. Thomason, “Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study,” Journal of Periodontology, vol. 70, no. 1, pp. 63–67, 1999.
[49]
G. Kaur, K. M. Verhamme, J. P. Dieleman et al., “Association between calcium channel blockers and gingival hyperplasia,” Journal of Clinical Periodontology, vol. 37, no. 7, pp. 625–630, 2010.
[50]
T. Tagawa, H. Nakamura, and M. Murata, “Marked gingival hyperplasia induced by nifedipine,” International Journal of Oral and Maxillofacial Surgery, vol. 19, no. 2, pp. 72–73, 1990.
[51]
L. Fattore, M. Stablein, G. Bredfeldt, T. Semla, M. Moran, and J. M. Doherty-Greenberg, “Gingival hyperplasia: a side effect of nifedipine and diltiazem,” Special Care in Dentistry, vol. 11, no. 3, pp. 107–109, 1991.
[52]
R. A. Seymour, “Effects of medications on the periodontal tissues in health and disease,” Periodontology 2000, vol. 40, no. 1, pp. 120–129, 2006.
[53]
M. Mavrogiannis, J. S. Ellis, J. M. Thomason, and R. A. Seymour, “The management of drug-induced gingival overgrowth,” Journal of Clinical Periodontology, vol. 33, no. 6, pp. 434–439, 2006.
[54]
S. G. Ciancio, “Medications' impact on oral health,” Journal of the American Dental Association, vol. 135, no. 10, pp. 1440–1480, 2004.
[55]
P. Ellgehausen, P. Elsner, and G. Burg, “Drug-induced lichen planus,” Clinics in Dermatology, vol. 16, no. 3, pp. 325–332, 1998.
[56]
B. H. Ackerman and N. Kasbekar, “Disturbances of taste and smell induced by drugs,” Pharmacotherapy, vol. 17, no. 3, pp. 482–496, 1997.
[57]
V. Musumeci, S. Di Salvo, B. Zappacosta, C. Zuppi, L. Colacicco, and P. Cherubini, “Salivary electrolytes in treated hypertensives at low or normal sodium diet,” Clinical and Experimental Hypertension, vol. 15, no. 2, pp. 245–256, 1993.
[58]
S. M. Popescu, M. Nechifor, M. Baniceru, O. Croitoru, and F. Popescu, “Effect of propranolol on mepivacaine serum concentrations in dental practice,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 105, no. 4, pp. e19–e23, 2008.
[59]
J. A. Yagiela, “Adverse drug interactions in dental practice: interactions associated with vasoconstrictors part V of a series,” Journal of the American Dental Association, vol. 130, no. 5, pp. 701–709, 1999.
[60]
S. F. Malamed, Handbook of Dental Anesthesia, Elsevier Mosby, St Louis, Mo, USA, 5 edition, 2004.
[61]
J. Little, D. Fallace, C. Miller, and N. Rhodus, Dental Management of the Medically Compromised Patient, Elsevier Mosby, St Louis, Mo, USA, 8 edition, 2013.
[62]
C. L. Hatch, B. Chernow, and G. T. Terezhalmy, “Plasma catecholamine and hemodynamic responses to the placement of epinephrine-impregnated gingival retraction cord,” Oral Surgery Oral Medicine and Oral Pathology, vol. 58, no. 5, pp. 540–544, 1984.
[63]
M. Greenberg, M. Glick, and M. Ship, Burket's Oral Medicine, BC Decker Inc, 11 edition, 2008.
[64]
D. Perloff, C. Grim, J. Flack et al., “Human blood pressure: determination by sphygmomanometry,” Circulation, vol. 88, no. 5, Part 1, p. 2460, 1993.
[65]
P. H. Gustavsen, A. Hoegholm, L. E. Bang, and K. S. Kristensen, “White coat hypertension is a cardiovascular risk factor: a 10-year follow-up study,” Journal of Human Hypertension, vol. 17, no. 12, pp. 811–817, 2003.
[66]
R. M. Conroy, K. Pyorala, A. P. Fitzgerald et al., “Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project,” European Heart Journal, vol. 24, no. 11, pp. 987–1003, 2003.
[67]
T. Sehestedt, J. Jeppesen, T. W. Hansen et al., “Risk prediction is improved by adding markers of subclinical organ damage to SCORE,” European Heart Journal, vol. 31, no. 7, pp. 883–891, 2010.
[68]
M. Volpe, A. Battistoni, G. Tocci, E. Agabiti Rosei, A. L. Catapano, and R. Coppo, “Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers,” Journal of Hypertension, vol. 30, pp. 1056–1064, 2012.
[69]
K. Pyorala, G. De Backer, I. Graham et al., “Prevention of coronary heart disease in clinical practice: recommendations of the task force of the European society of cardiology, European atherosclerosis society and European society of hypertension,” European Heart Journal, vol. 15, no. 10, pp. 1300–1331, 1994.
[70]
R. B. D'Agostino Sr., R. S. Vasan, M. J. Pencina et al., “General cardiovascular risk profile for use in primary care: the framingham heart study,” Circulation, vol. 117, no. 6, pp. 743–753, 2008.
[71]
J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, and M. Verschuren, “European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR),” European Heart Journal, vol. 33, no. 13, pp. 1635–1701, 2012.
